T0	Participants 91 114	after hip arthroplasty.
T1	Participants 212 242	primary total hip arthroplasty
T2	Participants 638 747	186 patients received either indomethacin 3 times daily, or rofecoxib twice, and 1 placebo, daily for 7 days.
T3	Participants 861 971	12 of the 186 patients included discontinued their medication before the end of the trial due to side effects.
T4	Participants 972 1029	The remaining 174 patients were included in the analysis.
T5	Participants 1030 1188	In the indomethacin group (n = 89), 77 patients (87%) showed no HO, 9 showed HO of grade 1 and 3 showed HO of grade 2 according to the Brooker classification.
T6	Participants 1189 1302	In the rofecoxib group (n = 85) 73 patients (86%) showed no ossification, 9 showed grade 1, and 3 showed grade 2.